Elbasvir / grazoprevir (new indication: chronic hepatitis C; adolescents from 12 to < 18 years)

Subject:

• Active Substance: Elbasvir / grazoprevir
• Name: Zepatier^®
• Therapeutic area: Chronic hepatitis C
• Pharmaceutical company: Merck Sharp & Dohme B.V.

Time table:

• Start: 15.11.2021
• Final decision by G-BA: 05.05.2022

Final decision:

• No additional benefit proved